IRCT20200405046953N1 IRCT 2020-04-06 Iranian Ministry of Health and Medical Education, Deputy of Research and Technology Comparison of therapies for COVID-19 Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial 2020-04-08 anticipated 3000 Complete https://irct.ir/trial/46930 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Given that this study is part of the SOLIDARITY Trial by the World Health Organization, the randomization method is only known by the Principal Investigators. Patients will be randomized through the study website equally between all the locally available treatment regimens (5 possibilities if all study drugs are locally available, fewer if not) • Local standard of care alone, OR local standard of care plus one of • Remdesivir (daily infusion for 10 days) • Chloroquine or Hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days) [NB Some collaborating hospitals will study chloroquine, others hydroxychloroquine] • Lopinavir with Ritonavir (orally twice daily for 14 days) • Lopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days). 3 COVID-19. Intervention 1: Intervention group: local standard of care plus Remdesivir (daily infusion for 10 days). Intervention 2: Intervention group: local standard of care plus Chloroquine or Hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days). Intervention 3: Intervention group: local standard of care plus Lopinavir with Ritonavir (orally twice daily for 14 days). Intervention 4: Intervention group: local standard of care plus Lopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days). Intervention 5: Control group: local standard of care. No - There is not a plan to make this available Justification or reason for not sharing IPD is Data collected in this study belongs to the World Health Organization SOLIDARITY Trial.